Off-the-shelf ATA188, an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy, was well tolerated across all 4 dose cohorts in patients with progressive multiple sclerosis (MS) in an open-label phase 1 study. There was a possible signal of therapeutic response, with a higher proportion of patients showing sustained disability improvement with increasing dose .
EBV is considered a risk factor in triggering MS. Mounting evidence suggests that EBV-infected immune cells, in particular memory B cells, play an important role in propagating both relapsing and progressive forms of MS. ATA188 offers a novel treatment approach selectively targeting and eliminating EBV-infected B cells and plasma cells in the circulation and central nervous system.
A phase 1a multicentre study assessed safety and efficacy of ATA188 in patients with progressive forms of MS. Patients were treated across 4 dose-escalating cohorts, with 6 patients each in cohorts 1...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Serum NfL predicts long-term clinical outcomes in MS Next Article
High NEDA rates after 2 years of ocrelizumab »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.